OptiNose Inc (OPTN)
1.16
0.00 (0.00%)
USD |
NASDAQ |
May 22, 16:00
1.16
0.00 (0.00%)
After-Hours: 20:00
OptiNose Enterprise Value: 210.13M for May 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 22, 2024 | 210.13M |
| May 21, 2024 | 210.13M |
| May 20, 2024 | 214.66M |
| May 17, 2024 | 221.44M |
| May 16, 2024 | 224.83M |
| May 15, 2024 | 212.96M |
| May 14, 2024 | 206.74M |
| May 13, 2024 | 211.26M |
| May 10, 2024 | 216.92M |
| May 09, 2024 | 205.61M |
| May 08, 2024 | 196.57M |
| May 07, 2024 | 195.44M |
| May 06, 2024 | 207.87M |
| May 03, 2024 | 193.18M |
| May 02, 2024 | 178.21M |
| May 01, 2024 | 181.67M |
| April 30, 2024 | 171.81M |
| April 29, 2024 | 176.13M |
| April 26, 2024 | 176.27M |
| April 25, 2024 | 181.31M |
| April 24, 2024 | 183.60M |
| April 23, 2024 | 188.40M |
| April 22, 2024 | 195.44M |
| April 19, 2024 | 180.09M |
| April 18, 2024 | 183.88M |
| Date | Value |
|---|---|
| April 17, 2024 | 194.31M |
| April 16, 2024 | 202.22M |
| April 15, 2024 | 213.53M |
| April 12, 2024 | 216.92M |
| April 11, 2024 | 219.18M |
| April 10, 2024 | 220.31M |
| April 09, 2024 | 218.05M |
| April 08, 2024 | 229.35M |
| April 05, 2024 | 228.22M |
| April 04, 2024 | 233.87M |
| April 03, 2024 | 235.00M |
| April 02, 2024 | 238.39M |
| April 01, 2024 | 241.78M |
| March 31, 2024 | 244.05M |
| March 28, 2024 | 221.01M |
| March 27, 2024 | 223.27M |
| March 26, 2024 | 223.27M |
| March 25, 2024 | 225.52M |
| March 22, 2024 | 240.17M |
| March 21, 2024 | 243.54M |
| March 20, 2024 | 249.74M |
| March 19, 2024 | 250.30M |
| March 18, 2024 | 274.52M |
| March 15, 2024 | 268.33M |
| March 14, 2024 | 270.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
87.60M
Minimum
Mar 23 2020
423.22M
Maximum
Nov 20 2019
223.16M
Average
204.48M
Median
Oct 04 2023
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 4.067B |
| Viking Therapeutics Inc | 5.985B |
| Zevra Therapeutics Inc | 184.06M |
| CytomX Therapeutics Inc | -3.796M |
| Spero Therapeutics Inc | -1.021M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.07M |
| Revenue (Quarterly) | 14.88M |
| Total Expenses (Quarterly) | 22.96M |
| EPS Diluted (Quarterly) | -0.12 |
| Gross Profit Margin (Quarterly) | 91.73% |
| Profit Margin (Quarterly) | -94.54% |
| Earnings Yield | -23.28% |
| Normalized Earnings Yield | -24.21 |